These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 17643778

  • 41. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
    El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK.
    J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874
    [Abstract] [Full Text] [Related]

  • 42. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J, Szer J, Fletcher JM, McGill J, Rowell JA, Wilson M.
    Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
    [Abstract] [Full Text] [Related]

  • 43. Pregnancy after avascular necrosis of the femur complicating Gaucher's disease.
    Cleary JE, Burke WM, Baxi LV.
    Am J Obstet Gynecol; 2001 Jan; 184(2):233-4. PubMed ID: 11174510
    [Abstract] [Full Text] [Related]

  • 44. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC, Chien YH, Lai MY, Hwu WL.
    J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
    [Abstract] [Full Text] [Related]

  • 45. Chitotriosidase genotype and plasma activity in patients type 1 Gaucher's disease and their relatives (carriers and non carriers).
    Giraldo P, Cenarro A, Alfonso P, Pérez-Calvo JI, Rubio-Félix D, Giralt M, Pocoví M.
    Haematologica; 2001 Sep; 86(9):977-84. PubMed ID: 11532627
    [Abstract] [Full Text] [Related]

  • 46. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
    Zimran A, Elstein D, Gonzalez DE, Lukina EA, Qin Y, Dinh Q, Turkia HB.
    Blood Cells Mol Dis; 2018 Feb; 68():153-159. PubMed ID: 27839979
    [Abstract] [Full Text] [Related]

  • 47. Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment.
    Mekinian A, Stirnemann J, Belmatoug N, Heraoui D, Fantin B, Fain O, Charpentier A, Rose C.
    Blood Cells Mol Dis; 2012 Jun 15; 49(1):53-7. PubMed ID: 22560483
    [Abstract] [Full Text] [Related]

  • 48. Rebound hepatosplenomegaly in type 1 Gaucher disease.
    Tóth J, Erdos M, Maródi L.
    Eur J Haematol; 2003 Feb 15; 70(2):125-8. PubMed ID: 12581195
    [Abstract] [Full Text] [Related]

  • 49. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
    Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ.
    Br J Haematol; 2009 Nov 15; 147(4):561-70. PubMed ID: 19732054
    [Abstract] [Full Text] [Related]

  • 50. Hematologic response in type I Gaucher's disease after enzyme replacement therapy.
    Parco S, Bruno G, Durighello M, Giorgini R, Simeone R, Bembi B.
    Haematologica; 1999 Apr 15; 84(4):376-7. PubMed ID: 10190956
    [No Abstract] [Full Text] [Related]

  • 51. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.
    de Fost M, van Noesel CJ, Aerts JM, Maas M, Pöll RG, Hollak CE.
    Haematologica; 2008 Jul 15; 93(7):1119-20. PubMed ID: 18519519
    [No Abstract] [Full Text] [Related]

  • 52. Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
    Arikan-Ayyildiz Z, Yüce A, Emre S, Baysoy G, Saltik-Temizel IN, Gürakan F.
    Turk J Pediatr; 2011 Jul 15; 53(5):499-507. PubMed ID: 22272449
    [Abstract] [Full Text] [Related]

  • 53. Ocular motor abnormalities in Gaucher disease.
    Harris CM, Taylor DS, Vellodi A.
    Neuropediatrics; 1999 Dec 15; 30(6):289-93. PubMed ID: 10706022
    [Abstract] [Full Text] [Related]

  • 54. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, Zimmermann A.
    J Inherit Metab Dis; 2007 Oct 15; 30(5):783-9. PubMed ID: 17703370
    [Abstract] [Full Text] [Related]

  • 55. [Gaucher's disease ].
    Belmatoug N, Caubel I, Stirnemann J, Billette de Villemeur T.
    J Soc Biol; 2002 Oct 15; 196(2):141-9. PubMed ID: 12360743
    [Abstract] [Full Text] [Related]

  • 56. [Gaucher's disease in childhood: presentation and treatment].
    Maaswinkel-Mooij PD, Kerstjens-Frederikse WS, de Koning J, Kok AJ, Poorthuis BJ.
    Tijdschr Kindergeneeskd; 1992 Dec 15; 60(6):231-5. PubMed ID: 1488736
    [Abstract] [Full Text] [Related]

  • 57. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.
    Stein P, Malhotra A, Haims A, Pastores GM, Mistry PK.
    J Inherit Metab Dis; 2010 Dec 15; 33(6):769-74. PubMed ID: 20683668
    [Abstract] [Full Text] [Related]

  • 58. Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy.
    Beutler E.
    Blood Cells Mol Dis; 2000 Aug 15; 26(4):303-6. PubMed ID: 11042031
    [No Abstract] [Full Text] [Related]

  • 59. Gaucher's disease;thirty-two years experience at Siriraj Hospital.
    Tanphaichitr VS, Suvatte V, Mahasandana C, Sachapong P, Veerakul G, Kankirawatana S, Wasant P.
    Southeast Asian J Trop Med Public Health; 1999 Aug 15; 30 Suppl 2():143-7. PubMed ID: 11400753
    [Abstract] [Full Text] [Related]

  • 60. Divergent phenotypes in Gaucher disease implicate the role of modifiers.
    Goker-Alpan O, Hruska KS, Orvisky E, Kishnani PS, Stubblefield BK, Schiffmann R, Sidransky E.
    J Med Genet; 2005 Jun 15; 42(6):e37. PubMed ID: 15937077
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.